Silo Pharma has entered into a commercial evaluation license agreement (CELA) for next-gen liposomes therapeutics to target multiple diseases, including...
Mindset Pharma and Canada’s top psychiatric research hospital, CAMH, have entered into a collaboration to build the molecular profile of MSP-1014 compared to psilocybin.
Ceruvia Lifesciences has submitted an FDA Investigational New Drug (IND) Application for its NYPRG-101 Migraine Prevention Program.
The US food and Drugs Administration (FDA) has given approval for MYCO-001 in a recent Investigational New Drug (IND) application, which will now be used in...
Psychedelic Health speaks to the founder of the Psychedelic Access and Research European Alliance (PAREA), Tadeusz Hawrot, about how the organisation aims to facilitate discussions around...
Ohio State University is launching The Center for Psychedelic Drug Research and Education (CPDRE).
Enosis Therapeutics has collaborated with Swinburne University and the Psychedelic Society of Belgium to carry out the study – finding that the use of virtual reality...
Dimensions has launched its new international plant medicine retreat series in Jamaica.
The partnership is aiming to collect and analyse digital biomarkers to identify signs of response and relapse in Beckley’s upcoming 5-MeO-DMT Phase 2 clinical trials.
A new study has revealed how ketamine works, which scientists say paves the way toward the development of safe, effective treatments for depression.
